AgingResearch.NewsJoin free

Beta-blockers and/or renin-angiotensin system inhibitors

Beta-blockers and/or renin-angiotensin system inhibitors has been studied in 1 paper since 2022: 1 observational study in people. The newest paper, Dec 11, 2022: “The Association Between Beta-blocker and Renin-Angiotensin System Inhibitor Use After Heart Failure With Reduced Ejection Fraction Hospitalization and Outcomes in Older Patients”.

Exposure

1 paper studies it2 findingsUpdated

See all 1 papers on beta-blockers and/or renin-angiotensin system inhibitors

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“(30-day hazard ratio 0.56, 95% confidence interval 0.45-0.70; 1-year hazard ratio 0.69, 95% confidence interval 0.61-0.78)”
The Association Between Beta-blocker and Renin-Angiotensin System Inhibitor Use After Heart Failure With Reduced Ejection Fraction Hospitalization and Outcomes in Older PatientsJournal of cardiac failure2022doi:10.1016/j.cardfail.2022.11.010

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Amarin Corporation and others
  • 2 of 2 findings with company ties
  • Humans1

What is beta-blockers and/or renin-angiotensin system inhibitors linked with?

2

Studies link beta-blockers and/or renin-angiotensin system inhibitors with 2 measures, most often 1-year mortality or readmission (1 study) and 1-year mortality (1).

1-year mortality or readmission

downin humans1

1 study

  1. Beta-blockers and/or renin-angiotensin system inhibitors are linked with a lower risk of 1-year mortality or readmission in humans (patients with hypotension, renal insufficiency or frailty; use at hospital discharge).

    “Even among the oldest patients, those over age 85, with hypotension, renal insufficiency or frailty, BB and/or RASi use at discharge was still associated with lower 1-year mortality or readmission.”

    Humanspatients with hypotension, renal insufficiency or frailty; use at hospital discharge1 year

    The Association Between Beta-blocker and Renin-Angiotensin System Inhibitor Use After Heart Failure With Reduced Ejection Fraction Hospitalization and Outcomes in Older Patients

    Journal of cardiac failure

1-year mortality

downin humans1HR 0.69

1 study

  1. Beta-blockers and/or renin-angiotensin system inhibitors are linked with a lower risk of 1-year mortality in humans (use at hospital discharge; overlap propensity-weighted Cox models) (HR 0.69, 95% CI 0.61-0.78).

    “(30-day hazard ratio 0.56, 95% confidence interval 0.45-0.70; 1-year hazard ratio 0.69, 95% confidence interval 0.61-0.78)”

    Humansuse at hospital discharge; overlap propensity-weighted Cox models1 yearn = 48,711

    The Association Between Beta-blocker and Renin-Angiotensin System Inhibitor Use After Heart Failure With Reduced Ejection Fraction Hospitalization and Outcomes in Older Patients

    Journal of cardiac failure

Latest

Related